TTI-101 is under clinical development by Tvardi Therapeutics and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase I drugs for Colorectal Cancer have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how TTI-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TTI-101 is under development for the treatment of unspecified cancers, solid tumors including breast cancer, metastatic hormone receptor-positive and HER2-negative breast cancer, head and neck squamous cell carcinoma, non-small cell lung cancer, metastatic hepatocellular carcinoma, colorectal cancer, gastric adenocarcinoma and melanoma, cachexia, skin, liver, inflammation, idiopathic pulmonary fibrosis, scleroderma and oropharyngeal cancer. It is administered intravenously and orally (in the form of hard capsule). The drug candidate act by targeting signal transducer and activator of transcription (STAT) 1 and 3. It was also under development for the treatment of inflammatory bowel disease.
Tvardi Therapeutics overview
Tvardi Therapeutics., is a biotechnology company that developing a new class of breakthrough medicines for diverse cancers. The company is headquartered in United States.
For a complete picture of TTI-101’s drug-specific PTSR and LoA scores, buy the report here.